Navigation

Multiple myeloma (first line) - bortezomib and thalidomide

Bortezomib and thalidomide for the first-line treatment of multiple myeloma

Status: History
Expected date of issue: July 2011
Referral date: March 2009
Process: MTA
Topic area:
  • Cancer
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Carina Righetti and Sally Doss
Communications manager: Alice Law
Project manager: Lori Farrar
Assessment Group / Evidence Review Group: Southampton Health Technology Assessment Centre (SHTAC) University of Southampton
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 8 October 2009
1st appraisal committee meeting: 13 April 2010
2nd appraisal committee meeting: 08 July 2010
3rd appraisal committee meeting: 09 May 2011
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Janssen-Cilag (bortezomib)
  • Celgene (thalidomide)

 

Patient / carer Groups

  • Leukaemia CARE
  • Macmillan Cancer Support
  • Myeloma UK
  • Rarer Cancers Foundation

Professional groups

  • British Society for Haematology
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians, Medical Oncology Joint Special Committee
  • UK Myeloma Forum

 

Others

  • Department of Health
  • Hammersmith and Fulham PCT
  • Welsh Assembly Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety - Northern Ireland (DHSSPSNI)
  • NHS Quality Improvement Scotland

 

Comparator manufacturers

  • GlaxoSmithKline (melphalan)

 

Relevant research groups

  • Leukaemia and Lymphoma Research
  • Clinical Trials Research Unit (CTRU), University of Leeds

 

Assessment Group

  • National Institute for Health Research Health Technology Assessment Programme
  • Southampton Health Technology Assessment Centre, University of Southampton

 

Associated Guideline Groups

  • National Collaborating Centre for Cancer

 

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
16 March 2011 Following the appeal decision, NICE have released an executable version of the economic model to Consultees and Commentators for consultation.  Following consultation comments will be discussed at the Appraisal Committee meeting on 9 May 2011.
Top


 

Key documents

This page was last updated: 27 July 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.